CA - Medexus Pharmaceuticals Inc. (MEDXF) Q3 2024 Earnings Call Transcript

2024-02-08 13:16:03 ET

Medexus Pharmaceuticals Inc. (MEDXF)

Q3 2024 Earnings Conference Call

February 8, 2024 8:00 AM ET

Company Participants

Victoria Rutherford – Investor Relations

Ken d’Entremont – Chief Executive Officer

Marcel Konrad – Chief Financial Officer

Conference Call Participants

Andre Uddin – Research Capital

Justin Keywood – Stifel

Stefan Quenneville – Echelon Capital Markets

Presentation

Operator

Greetings and welcome to the Medexus Third Fiscal Quarter 2024 Conference Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Victoria Rutherford, Investor Relations. Victoria, you may begin.

Victoria Rutherford

Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals third fiscal quarter 2024 earnings call. On the call this morning are Ken d’Entremont, Chief Executive Officer; and Marcel Konrad, Chief Financial Officer. If you have any questions after the conference call or would like further information about the company, please contact Adelaide Capital at 480-625-5772.

I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws. Actual results may differ materially from historical results or results anticipated by the forward-looking information. In addition, this discussion will also include non-GAAP measures, such as adjusted net income and loss and adjusted EBITDA, which do not have any standardized meaning under IFRS, and therefore may not be comparable to similar measures presented by other companies....

For further details see: